Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Schrodinger Inc SDGR

Technology Software - Application
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its... see more

Recent & Breaking News (NDAQ:SDGR)

Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus's TYK2 Inhibitor to Takeda

Business Wire February 14, 2023

Schrödinger to Announce Fourth Quarter and Full-Year 2022 Financial Results on February 28

Business Wire February 13, 2023

Qiming Venture Partners Backed Structure Therapeutics Successfully Debuts on Nasdaq

PR Newswire February 4, 2023

Schrödinger to Present at SVB Securities Global Biopharma Conference

Business Wire January 31, 2023

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 20, 2023

Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities

Business Wire January 9, 2023

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 16, 2022

Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting

Business Wire December 12, 2022

Schrödinger to Present at Piper Sandler 34th Annual Healthcare Conference

Business Wire November 21, 2022

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 18, 2022

Schrödinger to Present at Jefferies 13th Annual London Healthcare Conference

Business Wire November 7, 2022

Schrödinger Reports Third Quarter 2022 Financial Results

Business Wire November 3, 2022

Schrödinger To Present New Preclinical Data From Its CDC7 Inhibitor Program At American Society Of Hematology 2022 Annual Meeting

Business Wire November 3, 2022

Schrödinger to Announce Third Quarter 2022 Financial Results on November 3

Business Wire October 20, 2022

Schrödinger Hosts Platform Day

Business Wire October 6, 2022

Schrödinger to Host Platform Day on October 6, 2022

Business Wire September 20, 2022

Schrödinger to Present at Citi's 17th Annual BioPharma Conference

Business Wire August 31, 2022

Schrödinger Reports Inducement Grants To Newly Appointed Chief Financial Officer

Business Wire August 18, 2022

Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

Business Wire August 18, 2022

Schrödinger Reports Second Quarter 2022 Financial Results

Business Wire August 4, 2022